Literature DB >> 23375711

[Antineutrophil cytoplasmic autoantibodies in children: clinical features].

L Allard1, J-L Giniès, G Champion, A Chevailler, J-F Subra.   

Abstract

BACKGROUND: Antineutrophil cytoplasmic antibodies (ANCA) are usually considered as serological markers of vasculitis (microscopic polyangiitis, granulomatosis with polyangiitis, and Churg-Strauss syndrome), but they have also been described in other diseases. They are rarely observed in children. Therefore, this study aims to describe the clinical spectrum associated with positive ANCA in children. PATIENTS AND METHODS: All the children below 15 years of age, admitted to the Angers University Hospital between June 2004 and June 2010 presenting with an ANCA-positive test by indirect immunofluorescence were included in this study. The exhaustive list of ANCA-positive children was obtained from the immunology unit. Six antigenic targets were routinely tested by Elisa, i.e., proteinase 3, myeloperoxidase, bactericidal permeability increasing protein, cathepsin G, elastase, and lactoferrin. Clinical and biological data were retrospectively collected.
RESULTS: Thirty-seven children were identified with positive ANCA in this 6-year period. None of the antigenic targets tested was found in 21 patients. The most frequent diseases associated were inflammatory bowel disease (n=10), infections (n=6), hematological disease (n=5), and juvenile idiopathic arthritis (JIA) (n=4). Patients with JIA presented with a predominance of antielastase antibodies.
CONCLUSION: In contrast to the findings usually observed in adults, we obtained a wide spectrum of clinical entities associated with positive ANCA in this cohort. In children, the ANCA test has 2 advantages: to diagnose systemic vasculitis and to differentiate inflammatory bowel disease. Patients with JIA seemed to have more frequent antielastase antibodies: in the future, this finding should be further investigated in larger prospective studies.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23375711     DOI: 10.1016/j.arcped.2012.12.020

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  1 in total

1.  Exploring the Mechanism of Aspirin in the Treatment of Kawasaki Disease Based on Molecular Docking and Molecular Dynamics.

Authors:  Li Xiong; Junfeng Cao; Yixin Qiu; Yinyin Fu; Siyi Chen; Mengjia He; Shengyan Chen; Wei Xie; Xingyu Yang; Chaochao Wang; Mei Wu; Hengxiang Xu; Yijun Chen; Xiao Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-12       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.